Trial Profile

WAYFINDER: a Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children with SCN1A-positive Dravet Syndrome

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 06 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ETX 101 (Primary)
Indications Dravet syndrome
Focus Adverse reactions; Therapeutic Use
Acronyms Australia Only; WAYFINDER
Sponsors Encoded Therapeutics

Most Recent Events

27 Feb 2025 Planned End Date changed from 1 Dec 2029 to 1 Jun 2030.
27 Feb 2025 Planned primary completion date changed from 1 Dec 2029 to 1 Jun 2030.
13 Feb 2025 Completion of additional dose levels and reporting of preliminary safety and efficacy data are planned for 2H25.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com